Page last updated: 2024-12-05

2-phenyl-2-propanol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-phenylpropan-2-ol : A tertiary alcohol that is isopropanol in which the hydrogen attached to the carbon bearing the hydroxy group has been replaced by a phenyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID12053
CHEMBL ID3185495
CHEBI ID131607
SCHEMBL ID164244
MeSH IDM0068550

Synonyms (73)

Synonym
4-06-00-03219 (beilstein handbook reference)
je030bge05 ,
ec 210-539-5
2-phenylpropanol-2
unii-je030bge05
benzyl alcohol, .alpha.,.alpha.-dimethyl-
benzenemethanol, .alpha.,.alpha.-dimethyl-
nsc212537
nsc-212537
2-phenylpropan-2-ol
phenyldimethylcarbinol
2-phenylisopropanol
alpha-cumyl alcohol
benzyl alcohol, alpha,alpha-dimethyl-
ai3-05532
hsdb 5718
alpha,alpha-dimethylbenzyl alcohol
benzenemethanol, alpha,alpha-dimethyl-
alpha,alpha-dimethylbenzenemethanol
nsc 1261
brn 1905012
nsc 212537
einecs 210-539-5
nsc1261
dimethylphenylcarbinol
617-94-7
nsc-1261
1-hydroxycumene
2-phenyl-2-propanol
.alpha.,.alpha.-dimethylbenzyl alcohol
benzyl alcohol,.alpha.-dimethyl-
2-propanol, 2-phenyl-
dimethylphenylmethanol
.alpha.-cumyl alcohol
benzenemethanol,.alpha.-dimethyl-
inchi=1/c9h12o/c1-9(2,10)8-6-4-3-5-7-8/h3-7,10h,1-2h
2-phenyl-2-propanol, 97%
P0213
alpha,alpha-dimethylbenzyl aldohol
CHEBI:131607
NCGC00248623-01
AKOS009158102
2-phenyl-propan-2-ol
dtxcid107247
NCGC00258003-01
tox21_200449
cas-617-94-7
dtxsid3027247 ,
FT-0613314
PS-4036
2-phenylisopropanol [hsdb]
(1-hydroxy-1-methylethyl)benzene
dimethyl phenyl carbinol
dimethylphenyl carbinol
SCHEMBL164244
W-105093
STR08958
2-hydroxy-2-phenylpropane
1-methyl-1-phenylethanol
.alpha.,.alpha.-dimethylbenzenemethanol
CHEMBL3185495
a,a-dimethylbenzyl alcohol
2-phenylisopropyl alcohol
mfcd00004456
SY021550
Q15726116
AMY25731
P15346
A868634
PB47644
CS-W016526
EN300-120905
HY-W015810

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The highest tissue (14)C levels in rats were observed in adipose tissue, liver, and kidney with no accumulation observed after repeat dosing up to 7 days."( Disposition and metabolism of cumene in F344 rats and B6C3F1 mice.
Chen, LJ; Dix, KJ; Kramer, DJ; McDonald, JD; Sanders, JM; Thomas, LA; Wegerski, CJ, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
Mycoplasma genitalium metaboliteAny bacterial metabolite produced during a metabolic reaction in Mycoplasma genitalium.
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
tertiary alcoholA tertiary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has three other carbon atoms attached to it.
benzyl alcoholsCompounds containing a phenylmethanol skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency29.32460.006038.004119,952.5996AID1159521; AID1159523
progesterone receptorHomo sapiens (human)Potency65.73980.000417.946075.1148AID1346784
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency41.47900.003041.611522,387.1992AID1159552
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency58.59070.001530.607315,848.9004AID1224849
estrogen nuclear receptor alphaHomo sapiens (human)Potency65.73980.000229.305416,493.5996AID743079
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency52.21900.001723.839378.1014AID743083
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1393288Antibacterial activity against Staphylococcus aureus assessed as lowest concentration required for 7-log reduction in viable bacteria count after 1 hr2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
Quest for Novel Chemical Entities through Incorporation of Silicon in Drug Scaffolds.
AID1393287Antibacterial activity against Escherichia coli C3000 ATCC 15597 assessed as lowest concentration required for 7-log reduction in viable bacteria count after 1 hr2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
Quest for Novel Chemical Entities through Incorporation of Silicon in Drug Scaffolds.
AID1393290Antibacterial activity against Enterococcus faecalis ATCC 19433 assessed as lowest concentration required for 7-log reduction in viable bacteria count after 1 hr2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
Quest for Novel Chemical Entities through Incorporation of Silicon in Drug Scaffolds.
AID1393289Antibacterial activity against Pseudomonas aeruginosa ATCC 10145 assessed as lowest concentration required for 7-log reduction in viable bacteria count after 1 hr2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
Quest for Novel Chemical Entities through Incorporation of Silicon in Drug Scaffolds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (44.44)18.7374
1990's0 (0.00)18.2507
2000's2 (22.22)29.6817
2010's3 (33.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 57.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index57.24 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.46 (4.65)
Search Engine Demand Index87.84 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (57.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]